Hoppe's alkyl carbamate deprotonation methodology

Author(s):  
B.L.C. Noir
Keyword(s):  
2021 ◽  
Vol 322 ◽  
pp. 124520
Author(s):  
Kuan Shiong Khoo ◽  
Chien Wei Ooi ◽  
Kit Wayne Chew ◽  
Su Chern Foo ◽  
Pau Loke Show

Catalysts ◽  
2018 ◽  
Vol 8 (12) ◽  
pp. 579
Author(s):  
Yubo Ma ◽  
Lei Wang ◽  
Xiaodong Yang ◽  
Ronghui Zhang

TiO2/SiO2, Cr2O3-NiO/SiO2, and TiO2-Cr2O3/SiO2 were prepared by the impregnation method for alkyl carbamate synthesis using urea as the carbonyl source. Up to 97.5% methyl carbamate yield, 97% ethyl carbamate yield, and 96% butyl carbamate yield could be achieved, respectively. The catalysts were characterized by ICP-AES, BET, XRD, XPS, NH3-TPD, and EPMA. Catalytic activity investigation revealed that TiO2/SiO2, Cr2O3-NiO/SiO2, and TiO2-Cr2O3/SiO2 were effective catalysts for methyl carbamate (MC), ethyl carbamate (EC), and butyl carbamate (BC), respectively. The recycling tests suggested that these silica gel supported catalyst system is active, stable, and reusable. A total of 96–97% alkyl carbamate (methyl, ethyl, and butyl) could be obtained in a 2 L autoclave, and these data suggested that our catalyst system is relatively easy to scale up.


Langmuir ◽  
2005 ◽  
Vol 21 (2) ◽  
pp. 647-655 ◽  
Author(s):  
Kibum Kim ◽  
Katherine E. Plass ◽  
Adam J. Matzger

Chirality ◽  
2004 ◽  
Vol 16 (3) ◽  
pp. 139-146 ◽  
Author(s):  
Hana Navrátilová ◽  
Radka Opatřilová ◽  
Zdeněk Kříž ◽  
Jaroslav Koča

Tetrahedron ◽  
1994 ◽  
Vol 50 (34) ◽  
pp. 10367-10370 ◽  
Author(s):  
Sunita R. Deshpande ◽  
Anjali P. Likhite ◽  
Srinivasachari Rajappa
Keyword(s):  

1978 ◽  
Vol 9 (12) ◽  
Author(s):  
R. BOHRA ◽  
A. K. RAI ◽  
R. C. MEHROTRA

2021 ◽  
Vol 411 ◽  
pp. 128510
Author(s):  
Kuan Shiong Khoo ◽  
Chien Wei Ooi ◽  
Kit Wayne Chew ◽  
Su Chern Foo ◽  
Jun Wei Lim ◽  
...  

2021 ◽  
Vol 14 (4) ◽  
pp. 292
Author(s):  
Mai H. A. Mousa ◽  
Nermin S. Ahmed ◽  
Kai Schwedtmann ◽  
Efseveia Frakolaki ◽  
Niki Vassilaki ◽  
...  

Hepatitis C virus (HCV) is an international challenge. Since the discovery of NS5A direct-acting antivirals, researchers turned their attention to pursue novel NS5A inhibitors with optimized design and structure. Herein we explore highly potent hepatitis C virus (HCV) NS5A inhibitors; the novel analogs share a common symmetrical prolinamide 2,7-diaminofluorene scaffold. Modification of the 2,7-diaminofluorene backbone included the use of (S)-prolinamide or its isostere (S,R)-piperidine-3-caboxamide, both bearing different amino acid residues with terminal carbamate groups. Compound 26 exhibited potent inhibitory activity against HCV genotype (GT) 1b (effective concentration (EC50) = 36 pM and a selectivity index of >2.78 × 106). Compound 26 showed high selectivity on GT 1b versus GT 4a. Interestingly, it showed a significant antiviral effect against GT 3a (EC50 = 1.2 nM). The structure-activity relationship (SAR) analysis revealed that picomolar inhibitory activity was attained with the use of S-prolinamide capped with R- isoleucine or R-phenylglycine residues bearing a terminal alkyl carbamate group.


Sign in / Sign up

Export Citation Format

Share Document